Nurix Therapeutics shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating and announced a price target of $41.
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics shares rose after Jefferies initiated coverage with a Buy rating and set a price target of $41.
October 11, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies initiated coverage on Nurix Therapeutics with a Buy rating and a $41 price target, leading to a rise in the stock price.
The initiation of coverage by a major financial institution like Jefferies with a Buy rating and a specific price target is a strong positive signal for investors, likely leading to increased buying activity and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100